With strong efficacy, better tolerability for some, and easier administration, these therapies make incretin benefits more accessible
Most clinical guidance recommends: At 3 months: A1c recheck (HbA1c reflects the prior 3-month average, making this the earliest timepoint for meaningful assessment of glycemic response), metabolic panel if any GI side effects were significant At 6 months: Full panel repeat A1c, CMP, lipids, CBC to document treatment response comprehensively Annually: Full panel plus thyroid function, B12, and any additional markers relevant to your individual health picture If you experience severe or persistent gastrointestinal side effects, signs of dehydration, unusual fatigue, or any concerning symptoms, kidney function should be rechecked without waiting for a scheduled interval
Taurine reduction has also been reported in the corneas of aged mice 36
This innovative, non-invasive dosage form may support adherence for those seeking an alternative to injections
